Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
427
archived clinical trials in
Shingles

Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Troy, MI
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Troy, MI
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
St. Louis, MO
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Corning, NY
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Corning, NY
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Endwell, NY
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Endwell, NY
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Manlius, NY
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Manlius, NY
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Cleveland, OH
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Bristol, TN
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Murray, UT
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Charlottesville, VA
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Newport News, VA
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Richmond, VA
Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)
A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated:  1/19/2016
University of Colorado
mi
from
Aurora, CO
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated: 1/19/2016
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated:  1/19/2016
Emory University
mi
from
Atlanta, GA
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated: 1/19/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated:  5/30/2017
Auburn University
mi
from
Auburn, AL
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated: 5/30/2017
Auburn University
mi
from
Auburn, AL
Click here to add this to my saved trials
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated:  5/30/2017
Keck Graduate Institute School of Pharmacy
mi
from
Claremont, CA
Enhancing a Sustainable Pharmacy-based Immunization Program in Two States
Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States
Status: Enrolling
Updated: 5/30/2017
Keck Graduate Institute School of Pharmacy
mi
from
Claremont, CA
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Little Rock, AR
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Duarte, CA
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Duarte, CA
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Boston, MA
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Minnesota, MN
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Minnesota, MN
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Rochester, MN
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
New York, NY
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Durham, NC
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Cleveland, OH
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Frisco, CA
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Frisco, CA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Duarte, CA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Duarte, CA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
San Francisco, CA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Aurora, CO
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Westwood, KA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Westwood, KA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Lexington, KY
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Boston, MA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Boston, MA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Boston, MA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Detroit, MI
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Minnesota, MN
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Minnesota, MN
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Rochester, MN
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Hackensack, NJ
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
New York, NY
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Syracuse, NY
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Durham, NC
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Cleveland, OH
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated:  12/20/2017
GSK Investigational Site
mi
from
Dallas, TX
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status: Enrolling
Updated: 12/20/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials